

TheMARK

GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes

Diabetes Management

Issue 23 - March 2020

**Prepare for
Diabetes Alert Day,
March 24, 2020!**
How should GlycoMark test
results be interpreted?



Dear Healthcare Professionals,

Take advantage of **Diabetes Alert Day** to remind your patients of the importance of glycemic control!


ADD A GLYCOMARK test result to your patient's workup! The GlycoMark test is a shorter term (1-2 week) glycemic control indicator than A1C (2-3 months).

WHY ADD? You and your patient may find details about their glycemic control that isn't reported with A1C or sporadic self-monitored blood glucose.

HOW SHOULD GLYCOMARK TEST RESULTS BE INTERPRETED?

Once test results are received from the laboratory, refer to the Interpretation Guide:

- 1 Assess hyperglycemia and/or hyperglycemic excursions for the prior 1-2 weeks.
- 2 Compare two GlycoMark test results (previous to current) to assess glycemic control changes.
- 3 Analyze GlycoMark with A1C to identify glycemic control issues, far earlier than A1C alone.



Download Your GlycoMark Test Interpretation Guide!

[Download](#)

Educate Your Patients on the GlycoMark Test!

The GlycoMark test complements other tests for diabetes for a more complete assessment of glycemic control. The GlycoMark test can help you identify recent hyperglycemia and hyperglycemic excursions.


Download the GlycoMark “Know Both Your Numbers” [Patient Guide](#) and [Poster/Display](#) for printing.

How to Order the GlycoMark Test:

The GlycoMark test is available through numerous national and regional laboratories. Contact your preferred laboratory for information or download the NEW [GlycoMark Test Ordering Guide](#) to identify a laboratory and corresponding test codes.

The GlycoMark Test may be reimbursed by most federal, state and private payers, CPT 84378.

To order test kits for your laboratory, please refer to our [online resources](#) and [contact us](#)! We are happy to help support you in setting up the test on any open channel chemistry platform.



GlycoMark Test Product Package Insert, Revision G, 2017.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous

support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark [product insert](#) for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2020 GlycoMark, Inc. All Rights Reserved. M-97-1A



805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com